News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clovis Oncology (CLVS) Announces Encouraging Data From Phase 1/2a Study Evaluating Lucitanib In Advanced Solid Tumors



6/2/2014 9:42:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company’s novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRa-ß). Data from the study were presented today in an oral presentation by Professor Jean-Charles Soria at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES